High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer

References

• Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi:10.1016/j.eururo.2016.06.01027370177
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–475. doi:10.1016/j.eururo.2016.06.02027375033
   PubMed Web of Science ®Google Scholar
• Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Prim. 2017;3(17022):121–127. doi:10.1038/nrdp.2017.22
   Google Scholar
• James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–1488. doi:10.1056/NEJMoa110610622512481
   PubMed Web of Science ®Google Scholar
• Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–137. doi:10.1016/j.eururo.2014.02.03824613684
   PubMed Web of Science ®Google Scholar
• Mahe M, Dufour F, Neyret-Kahn H, et al. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med. 2018:1–18. doi:10.15252/emmm.20170816329180354
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa161368328212060
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. doi:10.1016/S0140-6736(16)32455-227939400
   PubMed Web of Science ®Google Scholar
• Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18. doi:10.1038/s41577-018-0044-0
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/nature2550129443960
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Getz G, Stuart JM, Korbel JO, Stein LD. Net – ICGC/TCGA pan-cancer analysis of whole genomes. Pan-cancer analysis of whole genomes. bioRxiv. 2017;3(10):162784. doi:10.1101/162784
   Google Scholar
• Henn BM, Botigué LR, Bustamante CD, Clark AG, Gravel S. Estimating the mutation load in human genomes. Nat Rev Genet. 2015;16(6):333–343. doi:10.1038/nrg393125963372
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199. doi:10.1056/NEJMoa140649825409260
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2016;348(6230):124. doi:10.1126/science.aaa1348
   Web of Science ®Google Scholar
• Horn T, Laus J, Seitz AK, et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016;34(2):181–187. doi:10.1007/s00345-015-1615-326055646
   PubMed Web of Science ®Google Scholar
• Sjödahl G, Lövgren K, Lauss M, et al. Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol Semin Orig Investig. 2014;32(6):791–797. doi:10.1016/j.urolonc.2014.02.007
   PubMed Web of Science ®Google Scholar
• Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci. 2007;104(10):3967–3972. doi:10.1073/pnas.061161810417360461
   PubMed Web of Science ®Google Scholar
• Danaher P, Warren S, Dennis L, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5(1):1–15. doi:10.1186/s40425-017-0215-828105368
   PubMedGoogle Scholar
• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540.e25–556.e25. doi:10.1016/j.cell.2017.09.007
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-426952546
   PubMed Web of Science ®Google Scholar
• Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012;14(5):468–474. doi:10.1007/s11912-012-0257-522878966
   PubMed Web of Science ®Google Scholar
• Korpal M, Puyang X, Wu ZJ, et al. Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. Nat Commun. 2017;8(1):1–14. doi:10.1038/s41467-017-00147-w28232747
   PubMedGoogle Scholar
• Rochel N, Krucker C, Coutos-Thévenot L, et al. Recurrent activating mutations of PPARγ associated with luminal bladder tumors. Nat Commun. 2019;10(1):253. doi:10.1038/s41467-018-08157-y30651555
   PubMedGoogle Scholar
• Lee H, Kim K, Woo J, et al. Quantitative proteomic analysis identifies AHNAK (Neuroblast differentiation-associated protein AHNAK) as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. Mol Cell Proteomics. 2018;17(9):1788–1802. doi:10.1074/mcp.RA118.00056229950347
   PubMed Web of Science ®Google Scholar